Описание
INN: Heparin sodium
Presentation: solution for intravenous and subcutaneous administration 5000 IU/ml 5 ml ampoules 5 units per pack
Included in EDL
MA number: R N002077/01
By prescription
Pharmacotherapeutic group: direct-action anticoagulant
Therapeutic indications:
• prevention and treatment of venous thrombosis (including thrombosis of the superficial and deep veins of the lower limbs; renal vein thrombosis) and pulmonary artery thromboembolism;
• prevention and treatment of thromboembolic complications associated with atrial fibrillation;
• prevention and treatment of peripheral arterial embolisms (including those associated with mitral heart disease);
• treatment of acute and chronic consumption coagulopathies (including stage I DIC);
• acute coronary syndrome without persistent ST-segment elevation on the ECG (unstable angina pectoris, myocardial infarction without ST-segment elevation on the ECG);
• prevention and treatment of venous thrombosis (including thrombosis of the superficial and deep veins of the lower limbs; renal vein thrombosis) and pulmonary artery thromboembolism;
• prevention and treatment of thromboembolic complications associated with atrial fibrillation;
• prevention and treatment of peripheral arterial embolisms (including those associated with mitral heart disease);
• treatment of acute and chronic consumption coagulopathies (including stage I DIC);
• acute coronary syndrome without persistent ST-segment elevation on the ECG (unstable angina pectoris, myocardial infarction without ST-segment elevation on the ECG);
• ST-elevation myocardial infarction: in thrombolytic therapy, primary percutaneous coronary revascularisation (balloon angioplasty with or without stenting) and at high risk of arterial or venous thrombosis and thromboembolism;
• prevention and therapy of microthrombosis and microcirculatory disorders, including haemolytic-uremic syndrome, glomerulonephritis (including lupus nephritis) and forced diuresis;
• prevention of blood clotting during haemotransfusion, in extracorporeal circulation systems (extracorporeal circulation during cardiac surgery, haemosorption, cytapheresis) and haemodialysis;
• treatment of vascular catheters.
• prevention and therapy of microthrombosis and microcirculatory disorders, including haemolytic-uremic syndrome, glomerulonephritis (including lupus nephritis) and forced diuresis;
• prevention of blood clotting during haemotransfusion, in extracorporeal circulation systems (extracorporeal circulation during cardiac surgery, haemosorption, cytapheresis) and haemodialysis;
• treatment of vascular catheters.
Shelf life: 4 years
Документы